A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C

Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer. Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking o...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, P, Jaiswal, A K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374494/
https://www.ncbi.nlm.nih.gov/pubmed/10755406
http://dx.doi.org/10.1054/bjoc.1999.1096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374494/
https://www.ncbi.nlm.nih.gov/pubmed/10755406
http://dx.doi.org/10.1054/bjoc.1999.1096

Ejemplares similares